| Disease stratification in GCA and PMR: state of the art and future perspectives A Tomelleri, KSM van der Geest, MA Khurshid, A Sebastian, F Coath, ... Nature Reviews Rheumatology 19 (7), 446-459, 2023 | 80 | 2023 |
| What is the current evidence for disease subsets in giant cell arteritis? KSM van der Geest, M Sandovici, Y van Sleen, JS Sanders, NA Bos, ... Arthritis & rheumatology 70 (9), 1366-1376, 2018 | 79 | 2018 |
| Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data AK Hemmig, D Gozzoli, L Werlen, H Ewald, M Aschwanden, D Blockmans, ... Seminars in Arthritis and Rheumatism 55, 152017, 2022 | 71 | 2022 |
| Involvement of monocyte subsets in the immunopathology of giant cell arteritis Y van Sleen, Q Wang, KSM van der Geest, J Westra, WH Abdulahad, ... Scientific reports 7 (1), 6553, 2017 | 66 | 2017 |
| Distinct macrophage phenotypes skewed by local granulocyte macrophage colony‐stimulating factor (GM‐CSF) and macrophage colony‐stimulating factor (M‐CSF) are associated with … WF Jiemy, Y van Sleen, KSM van der Geest, HA Ten Berge, ... Clinical & translational immunology 9 (9), e1164, 2020 | 65 | 2020 |
| Markers of angiogenesis and macrophage products for predicting disease course and monitoring vascular inflammation in giant cell arteritis Y van Sleen, M Sandovici, WH Abdulahad, J Bijzet, KSM van der Geest, ... Rheumatology 58 (8), 1383-1392, 2019 | 63 | 2019 |
| Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica Y Van Sleen, JC Graver, WH Abdulahad, KSM Van der Geest, AMH Boots, ... Frontiers in Immunology 10, 1981, 2019 | 55 | 2019 |
| A Distinct Macrophage Subset Mediating Tissue Destruction and Neovascularization in Giant Cell Arteritis: Implication of the YKL‐40/Interleukin‐13 Receptor α2 Axis Y Van Sleen, WF Jiemy, S Pringle, KSM Van der Geest, WH Abdulahad, ... Arthritis & Rheumatology 73 (12), 2327-2337, 2021 | 45 | 2021 |
| Decreased expression of negative immune checkpoint VISTA by CD4+ T cells facilitates T helper 1, T helper 17, and T follicular helper lineage differentiation in GCA R Hid Cadena, RD Reitsema, MG Huitema, Y Van Sleen, ... Frontiers in immunology 10, 1638, 2019 | 45 | 2019 |
| Comparison and validation of FDG-PET/CT scores for polymyalgia rheumatica KSM van der Geest, Y van Sleen, P Nienhuis, M Sandovici, N Westerdijk, ... Rheumatology 61 (3), 1072-1082, 2022 | 41 | 2022 |
| High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica Y van Sleen, AMH Boots, WH Abdulahad, J Bijzet, M Sandovici, ... Rheumatology 59 (1), 176-184, 2020 | 36 | 2020 |
| Functionally heterogenous macrophage subsets in the pathogenesis of giant cell arteritis: novel targets for disease monitoring and treatment I Esen, WF Jiemy, Y van Sleen, KSM van der Geest, M Sandovici, ... Journal of Clinical Medicine 10 (21), 4958, 2021 | 24 | 2021 |
| Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica Y van Sleen, P Therkildsen, BD Nielsen, KSM van der Geest, I Hansen, ... Arthritis Research & Therapy 24 (1), 65, 2022 | 22 | 2022 |
| Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage A Tomelleri, KSM van der Geest, A Sebastian, Y van Sleen, WA Schmidt, ... The Lancet Rheumatology 3 (12), e886-e895, 2021 | 21 | 2021 |
| Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica RD Reitsema, WF Jiemy, L Wekema, AMH Boots, P Heeringa, ... Frontiers in Immunology 13, 943574, 2022 | 19 | 2022 |
| Effect of DMARDs on the immunogenicity of vaccines Y van Sleen, KSM van der Geest, ALW Huckriede, D van Baarle, ... Nature Reviews Rheumatology 19 (9), 560-575, 2023 | 18 | 2023 |
| Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants? G Carvajal Alegria, M Nicolas, Y van Sleen Frontiers in Immunology 14, 1202160, 2023 | 16 | 2023 |
| Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort I Esen, S Arends, BD Nielsen, P Therkildsen, I Hansen, A van't Ende, ... RMD open 9 (1), e002640, 2023 | 15 | 2023 |
| Plasma Pyruvate Kinase M2 as a marker of vascular inflammation in giant cell arteritis I Esen, WF Jiemy, Y van Sleen, J Bijzet, DM de Jong, PH Nienhuis, ... Rheumatology 61 (7), 3060-3070, 2022 | 15 | 2022 |
| Indication of activated senescence pathways in the temporal arteries of patients with giant cell arteritis WF Jiemy, Y van Sleen, JC Graver, S Pringle, E Brouwer, ... Arthritis & Rheumatology 75 (10), 1812-1818, 2023 | 13 | 2023 |